Laboratory price list

Our men's tumour marker kit can help you find out about the types of tumours that most commonly affect men. The package includes laboratory measurements of tumour markers that are elevated in liver, stomach, colon, lung, prostate and testicular lesions.
Tumour markers may indicate disease recurrence or metastasis several months earlier than imaging or clinical symptoms.

They are not suitable for screening alone!
A negative result does not rule out the presence of a tumour!
Many tumour markers are non-specific!
When liver cells are formed, alpha-feto-protein (AFP) is produced. Levels are elevated in liver, ovarian and testicular cancer.
Among the test parameters, cancer antigen 19-9 (CA-19-9) may indicate the development of tumours of the pancreas, bile duct, colon, lung, gallbladder.
A cancer antigen 50 (CA-50) may indicate the presence of gastrointestinal tumours.
The main indication for CA 72-4 is the treatment of gastric cancer patients and the monitoring of disease progression.
β-2-Microglobulin (B2M) is produced by the body's immune system (B lymphocytes) or by tumour cells. It can also be used to diagnose certain kidney diseases (glomerular dysfunction). Levels are elevated in tumours affecting the haematopoietic system (multiple myeloma, lymphoma, B-cell chronic lymphocytic leukaemia, Hodgkin's disease, non-Hodgkin's lymphoma) and testis.
The carcino-embryonic antigen (CEA) is produced by embryonic and tumour cells. Levels are elevated in gastrointestinal tumours. Its value is also high in breast, lung, liver, pancreatic and ovarian cancers.
For non-small cell lung cancer (mainly squamous cell and large cell carcinoma subtypes), CYFRA 21-1 is considered the most suitable biomarker.
Human Chorionic Gonadotropin (HCG, free B-HCG) is produced in the cells of the placenta in women and plays a role in maintaining the corpus luteum during pregnancy.
In men, an elevated value may also indicate a pancreatic or testicular tumour.
Lactoferrin is an iron-binding protein that is also present in neutrophil granulocytes involved in the inflammatory immune response. Thus, its levels are measured in relation to the inflammatory processes in gastrointestinal diseases. Levels may also be elevated in colorectal tumours.
Calprotectin is a calcium-, zinc- and manganese-binding protein produced by neutrophil granulocytes and monocytes. Its levels may also be elevated in colorectal tumours.
Prostate-specific antigen (PSA) is produced by the epithelial cells of the prostate gland. PSA levels higher than 10 ng/ml are likely to indicate the presence of prostate cancer. For screening, the free PSA fraction and the total PSA/free PSA ratio are evaluated. Free PSA levels are lower in prostate cancer and higher in prostate enlargement.
Annual PSA screening is recommended for people over 45 years of age, as early diagnosis of malignant prostate cancer is curable.
The neuron-specific enolase (NSE) measurement is mainly used to monitor the effectiveness of therapy and to assess changes in the condition of patients with tumours, especially small-cell lung cancer and neuroblastoma.
The measurement of S-100 protein can be used to support the treatment of patients with malignant melanoma and to support the treatment of patients who have suffered a brain injury (traumatic brain injury or stroke).
Chromogranin A (CgA) can be used to diagnose neuroendocrine tumours and monitor therapy in treated patients. Neuroendocrine tumours can arise in almost any organ in the human body, most commonly arising in the mucosa of the gastrointestinal tract and pancreas, and the bronchial system. The concentration of chromogranin A correlates with disease activity and tumour size.
The squamous cell carcinoma (SCC) tumour marker can be used to follow squamous cell cancers.
Pro-gastrin-releasing peptide (ProGRP) is a sensitive marker of neuroendocrine tumours.

These tumour markers are not specific!
CA 19-9 levels may also be elevated in biliary cancer, pancreatitis, cystic fibrosis and liver disease.
Elevated serum levels of CA 72-4 may also occur in certain non-malignant diseases (e.g. pneumonia, pancreatitis, liver cirrhosis).

CEA levels can be elevated in inflammation, cirrhosis, ulcers and in heavy smokers.
Elevated CYFRA 21-1 levels have also been described in non-malignant diseases (e.g. pneumonia, sepsis) and abnormal kidney function.
High AFP values can also be obtained in cases of liver inflammation, cirrhosis, hepatitis.
β-2-Microglobulin (B2M) levels may also be elevated in renal inflammation, autoimmune diseases (systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjörgen syndrome (SjS)), Crohn's disease, and infections (cytomegalovirus (CMV), nonA-nonB hepatitis, mononucleosis infectiosa, HIV).
PSA levels can also rise in benign prostate enlargement.
Elevated NSE levels can also occur in malignant neuroendocrine diseases, many other tumour diseases and clinical pathologies.
Chromogranin A may also be elevated in pheochromocytoma, pancreatic and prostate tumours.

• Tumour markers (serum test): alpha-feto-protein (AFP), β-2-microglobulin (B2M), cancer antigen 19-9 (CA-19-9), cancer antigen 50 (CA-50), cancer antigen 72-4 (CA-72-4), carcino-embryonic antigen (CEA), chromogranin A (CgA), Cyfra-21-1, free β-Human Chorionic Gonadotropin (free β-HCG), prostate specific antigen (PSA), prostate specific antigen free (PSA free), neuron-specific enolase (NSE), S-100 protein, pro-gastrin-releasing peptide (ProGRP), squamous cell carcinoma (SCC)
• Stool tests: stool blood test, lactoferrin, calprotectin

Our male sex tumour marker kit can help you find out about the occurrence of tumours that most commonly affect men. The package includes laboratory measurements of tumour markers for liver, prostate, testicular lesions and elevated tumour markers for neuroendocrine tumours.
Tumour markers may indicate disease recurrence or metastasis several months earlier than imaging or clinical symptoms.

They are not suitable for screening alone!
A negative result does not rule out the presence of a tumour!
Many tumour markers are non-specific!
During the formation of liver cells alpha-feto-protein (AFP) Produced by. Levels are elevated in liver, ovarian and testicular cancer.
A β-2-microglobulin (B2M) produced by the body's immune system (B lymphocytes) or by tumour cells. The measurement can also be used to diagnose certain kidney diseases (glomerular dysfunction). Levels are elevated in haematopoietic system (multiple myeloma, lymphoma, B-cell chronic lymphocytic leukaemia, Hodgkin's disease, non-Hodgkin's lymphoma) and in tumours affecting the testis.
A Human Chorio-Gonadotropin (HCG, free B-HCG) in men may also indicate a pancreatic or testicular tumour.
A prostate specific antigen (PSA) produced by the epithelial cells of the prostate gland. A PSA level higher than 10 ng/ml indicates the presence of prostate cancer. At screening, the free PSA fraction and the total PSA/free PSA ratio are assessed. Free PSA levels are lower in prostate cancer and higher in prostate enlargement.
Annual PSA screening is recommended for people over 45 years of age, as early diagnosis of malignant prostate cancer is curable.
Chromogranin A (CgA) can be used to diagnose neuroendocrine tumours and monitor therapy in treated patients. Neuroendocrine tumours can arise in almost any organ in the human body, most commonly arising in the mucosa of the gastrointestinal tract and pancreas, and the bronchial system. The concentration of chromogranin A correlates with disease activity and tumour size.
These tumour markers are not specific!
High AFP values can also be obtained in cases of liver inflammation, cirrhosis, hepatitis.
β-2-Microglobulin (B2M) levels may also be elevated in renal inflammation, autoimmune diseases (systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjörgen syndrome (SjS)), Crohn's disease, and infections (cytomegalovirus (CMV), nonA-nonB hepatitis, mononucleosis infectiosa, HIV).
PSA levels can also rise in benign prostate enlargement.
Chromogranin A may also be elevated in pheochromocytoma, pancreatic and prostate tumours.

• Tumour markers (serum tests): alpha-feto-protein (AFP), β-2-microglobulin (B2M), free β-human chorionic gonadotropin (free β-HCG), chromogranin A(CgA), prostate-specific antigen (PSA), prostate-specific antigen free (PSA free)

Our gastrointestinal tumour marker package includes laboratory measurement of elevated tumour markers in liver, ovarian, colorectal and pancreatic lesions.

Tumour markers may indicate disease recurrence or metastasis several months earlier than imaging or clinical symptoms.

They are not suitable for screening alone!
A negative result does not rule out the presence of a tumour!
Many tumour markers are non-specific!
During the formation of liver cells alpha-feto-protein (AFP) Produced by. Levels are elevated in liver and ovarian cancer.
A cancer antigen 19-9 (CA-19-9) may indicate the development of tumours of the pancreas, bile ducts, colon, lungs, gall bladder.
A CA 72-4 is mainly indicated for the treatment of gastric and ovarian cancer patients and to monitor the progression of the disease.
A carcino-embryonic antigen (CEA) produced by embryonic and tumour cells. Levels are elevated in gastrointestinal tumours. Its value is also high in breast, lung, liver, pancreatic and ovarian cancers.
Cancer antigen 242 (CA-242) a tumour marker for colorectal cancer and pancreatic tumours.
A lactoferrin an iron-binding protein that is also present in neutrophil granulocytes involved in the inflammatory immune response. Thus, its levels are measured in relation to the inflammatory processes in gastrointestinal diseases. Levels may also be elevated in colorectal tumours.
A calprotectin calcium-, zinc- and manganese-binding protein produced by neutrophil granulocytes and monocytes. Levels may also be elevated in colorectal tumours.

These tumour markers are not specific!
High AFP values can also be obtained in cases of hepatitis, cirrhosis and hepatitis.
CA 19-9 levels may also be elevated in biliary cancer, pancreatitis, cystic fibrosis and liver disease.
Elevated serum levels of CA 72-4 may also occur in certain non-malignant diseases (e.g. pneumonia, pancreatitis, liver cirrhosis and ovarian cysts).
CEA levels can be elevated in inflammation, cirrhosis, ulcers and in heavy smokers.

• Tumour markers (serum tests): alpha-feto-protein (AFP), cancer antigen 19-9 (CA-19-9), cancer antigen 242 (CA-242), cancer antigen 72-4 (CA-72-4), carcino-embryonic antigen (CEA)
• Stool tests: stool blood test, lactoferrin, calprotectin

Our lung tumour marker package includes laboratory measurement of elevated tumour markers in lung lesions.
Tumour markers may indicate disease recurrence or metastasis several months earlier than imaging or clinical symptoms.

They are not suitable for screening alone!
A negative result does not rule out the presence of a tumour!
Many tumour markers are non-specific!
For non-small cell lung cancer, the CA 72-4 and the CYFRA 21-1 is considered the most suitable biomarker.

A carcino-embryonic antigen (CEA) produced by embryonic and tumour cells. Levels may also be elevated in lung tumours.
A neuron-specific enolase (NSE) measurement can be used to monitor the effectiveness of therapy and to assess changes in the condition of patients with tumours, particularly small-cell lung cancer and neuroblastoma.

These tumour markers are not specific!
Elevated serum levels of CA 72-4 may also occur in certain non-malignant diseases (e.g. pneumonia, pancreatitis, liver cirrhosis and ovarian cysts).
CEA levels can be elevated in inflammation, cirrhosis, ulcers and in heavy smokers.
Elevated CYFRA 21-1 levels have also been described in non-malignant diseases (e.g. pneumonia, sepsis) and abnormal kidney function.
Elevated NSE levels can also occur in malignant neuroendocrine diseases, many other tumour diseases and clinical pathologies.

• Tumour markers (serum tests): cancer antigen 72-4 (CA-72-4), carcinoembryonic antigen (CEA), Cyfra-21-1, neuron-specific enolase (NSE)

Our women's tumour marker kit can help you find out about the types of tumours that most commonly affect women. The package includes laboratory measurements of tumour markers for liver, ovarian, breast, stomach, colon, pancreas and lung lesions.
Tumour markers may indicate disease recurrence or metastasis several months earlier than imaging or clinical symptoms.

They are not suitable for screening alone!
A negative result does not rule out the presence of a tumour!
Many tumour markers are non-specific!
During the formation of liver cells alpha-feto-protein (AFP) Produced by. Levels are elevated in liver, ovarian and testicular cancer.
The test parameters are cancer antigen 125 II (CA-125) the ovaries, the cancer antigen 19-9 (CA-19-9) the pancreas, bile ducts, large intestine, lungs, gall bladder, the cancer antigen 15-3 (CA-15-3) and may indicate the development of tumours of the breast, colon, lung.
The main indications for CA 72-4 are the treatment of patients with gastric and ovarian cancer and the monitoring of disease progression.
A β-2-microglobulin (B2M) produced by the body's immune system (B lymphocytes) or by tumour cells. The measurement can also be used to diagnose certain kidney diseases (glomerular dysfunction). Levels are elevated in tumours affecting the haematopoietic system (multiple myeloma, lymphoma, B-cell chronic lymphocytic leukaemia, Hodgkin's disease, non-Hodgkin's lymphoma).
A carcino-embryonic antigen (CEA) is produced by embryonic and tumour cells. Levels are elevated in gastrointestinal tumours. Its value is also high in breast, lung, liver, pancreatic and ovarian cancers.
For non-small cell lung cancer (mainly squamous cell and large cell carcinoma subtypes), CYFRA 21-1 is considered the most suitable biomarker.
A Human Chorio-Gonadotropin (HCG) is formed in the cells of the placenta and plays a role in maintaining the corpus luteum during pregnancy.
Levels are elevated from the first week after conception to 8-10 weeks, so it is an excellent indicator of pregnancy. Otherwise, an elevated level can indicate ovarian, placental, pancreatic, breast or, in men, testicular tumours.
Cancer antigen 242 (CA-242) a tumour marker for colorectal cancer and pancreatic tumours.
Chromogranin A (CgA) can be used to diagnose neuroendocrine tumours and monitor therapy in treated patients. Neuroendocrine tumours can arise in almost any organ in the human body, most commonly arising in the mucosa of the gastrointestinal tract and pancreas, and the bronchial system. The concentration of chromogranin A correlates with disease activity and tumour size.
A human epididymis protein 4 (HE4) is a tumour marker for ovarian cancer, which has high levels in ovarian cancer. The determination of HE4 concentration is also useful in monitoring malignant ovarian cancer that has been diagnosed and treated.
A lactoferrin an iron-binding protein that is also present in neutrophil granulocytes involved in the inflammatory immune response. Thus, its levels are measured in relation to the inflammatory processes in gastrointestinal diseases. Levels may also be elevated in colorectal tumours.
A calprotectin calcium-, zinc- and manganese-binding protein produced by neutrophil granulocytes and monocytes. Levels may also be elevated in colorectal tumours.
The neuron-specific enolase (NSE) measurement is mainly used to monitor the effectiveness of therapy and to assess changes in the condition of patients with tumours, especially small-cell lung cancer and neuroblastoma.
The measurement of S-100 protein can be used to support the treatment of patients with malignant melanoma and to support the treatment of patients who have suffered a brain injury (traumatic brain injury or stroke).

These tumour markers are not specific!
CA-125 levels can also be high in menstruation, pregnancy and pelvic inflammatory disease.
CA 19-9 levels may also be elevated in biliary cancer, pancreatitis, cystic fibrosis and liver disease.
CA 15-3 levels may also be elevated in liver and breast inflammation.
Elevated serum levels of CA 72-4 may also occur in certain non-malignant diseases (e.g. pneumonia, pancreatitis, liver cirrhosis and ovarian cysts).
CEA levels can be elevated in inflammation, cirrhosis, ulcers and in heavy smokers.
Elevated CYFRA 21-1 levels have also been described in non-malignant diseases (e.g. pneumonia, sepsis) and abnormal kidney function.
High AFP values can also be obtained in cases of hepatitis, cirrhosis and hepatitis.
β-2-microglobulin (B2M) levels may also be elevated in renal inflammation, autoimmune diseases (systemic lupus erythematosus (SLE)), rheumatoid arthritis (RA), Sjörgen syndrome (SjS), Crohn's disease, and infections (cytomegalovirus (CMV), nonA-nonB hepatitis, mononucleosis infectiosa, HIV).
Elevated NSE levels can also occur in malignant neuroendocrine diseases, many other tumour diseases and clinical pathologies.
Chromogranin A may also be elevated in pheochromocytoma, pancreatic and prostate tumours.

• Tumour markers (serum tests): alpha-feto-protein (AFP), β-2-microglobulin (B2M), cancer antigen 125 II (CA-125), cancer antigen 15-3 (CA-15-3), cancer antigen 19-9 (CA-19-9), cancer antigen 242 (CA-242), cancer antigen 50 (CA-50), cancer antigen 72-4 (CA-72-4), carcino-embryonic antigen (CEA), chromogranin A (CgA), Cyfra-21-1, human chorionic gonadotropin (HCG), human epididymis protein 4 (HE4), neuron-specific enolase (NSE), S-100 protein, pro-gastrin-releasing peptide (ProGRP), squamous cell carcinoma (SCC)
• Stool tests: stool blood test, lactoferrin, calprotectin

Our female sex tumour marker package includes laboratory measurement of tumour markers that are elevated in liver, ovarian, breast and neuroendocrine tumours.

Tumour markers may indicate disease recurrence or metastasis several months earlier than imaging or clinical symptoms.

They are not suitable for screening alone!
A negative result does not rule out the presence of a tumour!
Many tumour markers are non-specific!
During the formation of liver cells alpha-feto-protein (AFP) Produced by. Levels are elevated in liver and ovarian cancer.
The test parameters are cancer antigen 125 II (CA-125) the ovaries, the cancer antigen 15-3 (CA-15-3) may indicate the development of a breast tumour in particular.
A CA 72-4 is mainly indicated for the treatment of gastric and ovarian cancer patients and to monitor the progression of the disease.
A carcino-embryonic antigen (CEA) produced by embryonic and tumour cells. Its value can be high in breast, lung, liver, pancreatic and ovarian cancers.
A Human Chorio-Gonadotropin (HCG) is formed in the cells of the placenta and plays a role in maintaining the corpus luteum during pregnancy.
Levels are elevated from the first week after conception to 8-10 weeks, so it is an excellent indicator of pregnancy. Otherwise, an elevated level can indicate ovarian, placental, pancreatic or breast tumours.
Chromogranin A (CgA) can be used to diagnose neuroendocrine tumours and monitor therapy in treated patients. Neuroendocrine tumours can arise in almost any organ in the human body, most commonly arising in the mucosa of the gastrointestinal tract and pancreas, and the bronchial system. The concentration of chromogranin A correlates with disease activity and tumour size.
A human epididymis protein 4 (HE4) is a tumour marker for ovarian cancer, which has high levels in ovarian cancer. The determination of HE4 concentration is also useful in monitoring malignant ovarian cancer that has been diagnosed and treated.
These tumour markers are not specific!
High AFP values can also be obtained in cases of hepatitis, cirrhosis and hepatitis.
CA-125 levels can also be high in menstruation, pregnancy and pelvic inflammatory disease.
CA 15-3 levels may also be elevated in liver and breast inflammation.
Elevated serum levels of CA 72-4 may also occur in certain non-malignant diseases (e.g. pneumonia, pancreatitis, liver cirrhosis and ovarian cysts).
CEA levels can be elevated in inflammation, cirrhosis, ulcers and in heavy smokers.
Chromogranin A may also be elevated in pheochromocytoma, pancreatic and prostate tumours.

• Tumour markers (serum tests): alpha-feto-protein (AFP), cancer antigen 125 II (CA-125), cancer antigen 15-3 (CA-15-3), cancer antigen 72-4 (CA-72-4), carcino-embryonic antigen (CEA), chromogranin A (CgA), human chorionic gonadotropin (HCG), human epididymis protein 4 (HE4)